TABLE 2.
Pathway annotation by DAVID
Pathways | Genes | p Value |
---|---|---|
KEGG database | ||
Pathways in cancer | E2F1, AR, RXRA, PPARG, TP53, FOXO1, NFKB1, RB1, STAT1, STAT3, FOS, HDAC2, EP300, HIF1A, ETS1, JUN, MYC | 2.24E-09 |
Prostate cancer | E2F1, AR, ATF4, EP300, CREB1, TP53, FOXO1, NFKB1, RB1 | 4.65E-07 |
Cell cycle | E2F1, RAD21, EP300, HDAC2, E2F4, TP53, RB1, MYC, SMC3 | 6.24E-06 |
Huntington disease | SIN3A, EP300, HDAC2, SP1, CREB1, PPARG, TP53, TBP, PPARGC1A | 8.87E-05 |
Pancreatic cancer | E2F1, TP53, NFKB1, RB1, STAT1, STAT3 | 2.80E-04 |
Chronic myeloid leukemia | E2F1, HDAC2, TP53, NFKB1, RB1, MYC | 3.39E-04 |
Small cell lung cancer | E2F1, RXRA, TP53, NFKB1, RB1, MYC | 5.74E-04 |
Maturity onset diabetes of young | HNF1A, HNF4A, FOXA2, HNF4G | 0.0011 |
Thyroid cancer | RXRA, PPARG, TP53, MYC | 0.0016 |
Adipocytokine signaling pathway | PPARA, RXRA, NFKB1, PPARGC1A, STAT3 | 0.0021 |
Bladder cancer | E2F1, TP53, RB1, MYC | 0.0048 |
MAPK signaling | FOS, ATF4, JUN, JUND, TP53, NFKB1, SRF, MYC | 0.0056 |
Non-small cell lung cancer | E2F1, RXRA, TP53, RB1 | 0.0097 |
BioCarta database | ||
METS effect on macrophage differentiation | E2F1, FOS, SIN3A, HDAC2, E2F4, ETS1, JUN | 3.22E-06 |
CARM1 and regulation of the estrogen receptor | EP300, HDAC2, GTF2F1, ESR1, TBP, PPARGC1A, BRCA1 | 5.82E-05 |
Mechanism of gene regulation by peroxisome proliferators via PPAR | PPARα, EP300, SP1, JUN, RXRA, RB1, PPARγC1A | 0.0012 |
Role of PPAR-γ coactivators in obesity and thermogenesis | EP300, RXRA, PPARG, PPARGC1A | 0.0019 |
Oxidative stress-induced gene expression via Nrf2 | MAFF, FOS, JUN, CREB1, MAFK | 0.0019 |
IL-6 signaling pathway | FOS, CEBPB, JUN, SRF, STAT3 | 0.0019 |
PDGF signaling pathway | FOS, JUN, STAT1, SRF, STAT3 | 0.0056 |
EGF signaling pathway | FOS, JUN, STAT1, SRF, STAT3 | 0.0064 |
Human cytomegalovirus and map kinase pathways | SP1, CREB1, NFKB1, RB1 | 0.0072 |
Hypoxia-inducible factor in the cardiovascular system | HIF1A, EP300, JUN, CREB1 | 0.0088 |